Stephen F Brandon

US Patent:

20060252830, Nov 9, 2006

Filed:

May 6, 2005

Appl. No.:

11/123284

Inventors:

Stephen Brandon - Roanoke TX, US
Christopher Offen - Marietta GA, US
Charles Harrison - Marietta GA, US
Jeffrey Kluger - West Hartford CT, US
Charles White - Newington CT, US

International Classification:

A61K 31/19

US Classification:

514557000

Abstract:

A method for the treatment of depleted intracellular and serum magnesium levels by administration of a highly bioavailable magnesium salt is disclosed. A prescription dispensing system is also disclosed. The highly bioavailable magnesium salt can be administered alone or as adjunctive therapy in conjunction with various medications that cause or exacerbate depleted intracellular magnesium levels, such as renal magnesium wasting medications, including diuretics, immunosuppressants, chemotherapeutic agents, and antibiotics. The highly bioavailable magnesium salt can also be used as adjunctive therapy in conjunction with Class III anti-arrhythmic drugs to attenuate the QTc interval and reduce the risk of fatal arrhythmias, which are a common risk associated with Class III anti-arrhythmic drugs. The administration of a highly bioavailable magnesium salt in accordance with the present invention also serves to restore intracellular potassium levels to normal ranges in patients who remain hypokalemic despite potassium therapy.

US Patent:

20060252831, Nov 9, 2006

Filed:

May 6, 2005

Appl. No.:

11/123285

Inventors:

Christopher Offen - Marietta GA, US
Stephen Brandon - Roanoke TX, US

International Classification:

A61K 31/19

US Classification:

514557000

Abstract:

A method for the treatment of depleted intracellular and serum magnesium levels by administration of a highly bioavailable magnesium salt is disclosed. A prescription dispensing system is also disclosed. The highly bioavailable magnesium salt can be administered alone or as adjunctive therapy in conjunction with various medications that cause or exacerbate depleted intracellular magnesium levels, such as renal magnesium wasting medications, including diuretics, immunosuppressants, chemotherapeutic agents, and antibiotics. The highly bioavailable magnesium salt can also be used as adjunctive therapy in conjunction with Class III anti-arrhythmic drugs to attenuate the QTc interval and reduce the risk of fatal arrhythmias, which are a common risk associated with Class III anti-arrhythmic drugs. The administration of a highly bioavailable magnesium salt in accordance with the present invention also serves to restore intracellular potassium levels to normal ranges in patients who remain hypokalemic despite potassium therapy.

US Patent:

20100074960, Mar 25, 2010

Filed:

May 18, 2009

Appl. No.:

12/467883

Inventors:

Stephen F. Brandon - Trophy Club TX, US
Feng Zhang - Austin TX, US
Stuart Schoenherr - Beeville TX, US

International Classification:

A61K 9/14
A61K 31/22
A61P 43/00

US Classification:

424490, 514546, 424489

Abstract:

Disclosed are high-loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and exhibit a controlled release dissolution profile. Also disclosed are methods for making controlled release dosage forms for oral administration of a therapeutically effective amount of magnesium salt to a mammal. Also disclosed are methods for treating a disorder characterized by magnesium deficiency and methods for preventing or alleviating low magnesium levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

US Patent:

20130224264, Aug 29, 2013

Filed:

Apr 9, 2013

Appl. No.:

13/859098

Inventors:

Stephen F. Brandon - Trophy Club TX, US
Feng Zhang - Burlingame CA, US
Stuart Schoenherr - Beeville TX, US

Assignee:

PHARMALYTE SOLUTIONS, LLC - Southlake TX

International Classification:

A61K 33/06

US Classification:

424400, 424682

Abstract:

Disclosed are high loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and exhibit a controlled release dissolution profile. Also disclosed are methods for making controlled release dosage forms for oral administration of a therapeutically effective amount of magnesium salt to a mammal. Also disclosed are methods for treating a disorder characterized by magnesium deficiency and methods for preventing or alleviating low magnesium levels.

US Patent:

20140121273, May 1, 2014

Filed:

Mar 25, 2013

Appl. No.:

13/849946

Inventors:

Christopher Offen - Marietta GA, US
Stephen F. Brandon - Roanoke TX, US

Assignee:

PHARMALYTE SOLUTIONS, LLC - Southlake TX

International Classification:

A61K 31/19

US Classification:

514557

Abstract:

A method for the treatment of depleted intracellular and serum magnesium levels by administration of a highly bioavailable magnesium salt is disclosed. A prescription dispensing system is also disclosed. The highly bioavailable magnesium salt can be administered alone or as adjunctive therapy in conjunction with various medications that cause or exacerbate depleted intracellular magnesium levels, such as renal magnesium wasting medications, including diuretics, immunosuppressants, chemotherapeutic agents, and antibiotics. The highly bioavailable magnesium salt can also be used as adjunctive therapy in conjunction with Class III anti-arrhythmic drugs to attenuate the QTc interval and reduce the risk of fatal arrhythmias, which are a common risk associated with Class III anti-arrhythmic drugs. The administration of a highly bioavailable magnesium salt also serves to restore intracellular potassium levels to normal ranges in patients who remain hypokalemic despite potassium therapy.